Do novel pharmacological therapies (Zilebesiran, lorundrostat, baxdrostat) lower blood pressure and improve outcomes in patients with hypertension?
Novel therapies such as Zilebesiran, lorundrostat, and baxdrostat show significant potential for hypertension management, highlighting future challenges in reimbursement and healthcare implementation once licensed.
Novel therapies (Zilebesiran, lorundrostat, baxdrostat) have shown great potential in lowering BP that is clinically meaningful to help improve cardiovascular and renal outcomes. ASI therapies lorundrostat and baxdrostat are close to being licensed for HTN. Once commercially available and recommended in treatment guidelines, the next big challenge will be reimbursement and implementation model in different healthcare systems.
Building similarity graph...
Analyzing shared references across papers
Loading...
Current Opinion in Nephrology & Hypertension
Queen Mary University of London
UCL Biomedical Research Centre
Add This Paper to Your Research Feed
Any time a new paper drops it will be there.
Saxena et al. (Fri,) studied this question.